



Dicerna™ to Present at Upcoming Investor Conferences

February 18, 2020

LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 18, 2020-- [Dicerna Pharmaceuticals, Inc.](#) (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present a corporate overview at two upcoming investor conferences:

- **9th Annual Leerink Partners Global Healthcare Conference** in New York City on Tuesday, Feb. 25, 2020 at 9:30 a.m. ET.
- **Cowen and Company 40th Annual Healthcare Conference** in Boston on Monday, March 2, 2020 at 11:20 a.m. ET.

A live audio webcast of both presentations will be accessible from the Investors and Media section of the Dicerna website at www.investors.dicerna.com. Archived replays will be available on the Company's website for a period of 90 days after each conference.

About Dicerna™Pharmaceuticals, Inc.

Dicerna™Pharmaceuticals, Inc., is a biopharmaceutical company using ribonucleic acid interference (RNAi) to develop medicines that silence genes that cause disease. The Company's proprietary GalXC™ technology is being applied to develop potent, selective and safe RNAi therapies to treat diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases and viral infectious diseases. Dicerna aims to treat disease by addressing the underlying causes of illness with capabilities that extend beyond the liver to address a broad range of diseases, focusing on target genes where connections between gene and disease are well understood and documented. Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. Dicerna has strategic collaborations with Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc. and Boehringer Ingelheim International GmbH. For more information, please visit www.dicerna.com.

Cautionary Note on Forward-Looking Statements

This press release includes forward-looking statements pertaining to continued service of employees and future vesting of inducement grants. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those relating to our preclinical research and other risks identified under the heading "Risk Factors" included in our most recent Form 10-Q filing and in other future filings with the SEC. The forward-looking statements contained in this press release reflect Dicerna's current views with respect to future events, and Dicerna does not undertake and specifically disclaims any obligation to update any forward-looking statements.

Dicerna™ and GalXC™ are trademarks of Dicerna Pharmaceuticals, Inc.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20200218005979/en/>

Source: Dicerna™Pharmaceuticals, Inc.

Media:

Amy Trevvett, Dicerna Pharmaceuticals, Inc.
+1 617-612-6253
atrevvett@dicerna.com

Alex Van Rees, SmithSolve
+1 973-442-1555 ext. 111
alex.vanrees@smithsolve.com

Investors:

Lauren Stival, Stern Investor Relations, Inc.
+1 212-362-1200
lauren.stival@sternir.com